Additionally, the cladogram highlighted the large variety of microbes identified within the Firmicutes phyla, which was much greater than the microbe variation found in the other phyla
Updated on January 2, 2024 Medically Reviewed Litigation Guides Ozempic and Wegovy, treatments for type 2 diabetes, have potential links to gastrointestinal issues
Mindset Becomes the Key Tool: Recognizing this phase as part of the process keeps people focused
doi:10.1006/jmbi.1993.1376
Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved
doi:10.1093/advances/nmx011
